AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27021357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention package
Number of subjects: 1998
Study 27021357 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1998
Study 25566618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Sanyu Decoction (BHSD)
Number of subjects: 70
Study 25566618 — intervention group
Group type: COMPARATOR
Intervention: Mirena
Number of subjects: 70
Study 22233522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) conversion regimen
Number of subjects: 607
Study 22233522 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI) continuation
Number of subjects: 607
Study 20107216 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal tocodynamometry
Number of subjects: 1456
Study 20107216 — intervention group
Group type: COMPARATOR
Intervention: External monitoring
Number of subjects: 1456
Study 17643617 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless xenograft aortic valve replacement
Number of subjects: 223
Study 17643617 — intervention group
Group type: COMPARATOR
Intervention: Conventional stented xenograft aortic valve replacement
Number of subjects: 223
Study 17643617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 223
Study 16245354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) for 5 years (20 mg/day)
Number of subjects: 1901
Study 16245354 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) for 2 years (20 mg/day)
Number of subjects: 1901
Study 11886196 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated central venous catheter (CVC)
Number of subjects: 157
Study 11886196 — intervention group
Group type: COMPARATOR
Intervention: Commercially available central venous catheter (CVC)
Number of subjects: 157
Study 11886196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SC and CC)
Number of subjects: 157
Study 9808930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive psychotherapy
Number of subjects: 100
Study 9808930 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychotherapy
Number of subjects: 100
Study 9808930 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 100
Study 7660449 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg DEC once daily for 12 days
Number of subjects: 0
Study 7660449 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg DEC given 3 times daily for 12 days
Number of subjects: 0
Study 7660449 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 treatment regimens (6 mg/kg once daily, 2 mg/kg three times daily, and unspecified third regimen)
Number of subjects: 0
Study 2913493 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient detoxification with decreasing doses of oxazepam
Number of subjects: 164
Study 2913493 — intervention group
Group type: COMPARATOR
Intervention: Inpatient detoxification with oxazepam and rehabilitation treatment
Number of subjects: 164
Study 2913493 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient detoxification
Number of subjects: 164
Study 2913493 — intervention group
Group type: COMPARATOR
Intervention: Inpatient detoxification
Number of subjects: 164
Study 2913493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study 972787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin with blue light energy of 6-7 muW/cm2
Number of subjects: 24
Study 972787 — intervention group
Group type: COMPARATOR
Intervention: Control group with blue light energy of 8-10 muW/cm2
Number of subjects: 24
Study 972787 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-treated infants receiving less energy than control (6-7 muW/cm2)
Number of subjects: 24
Study 7303703 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg beta‐methyldigoxin (Lanitop) daily, orally
Number of subjects: 24
Study 7303703 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg beta‐acetyldigoxin (Novodigal) daily, orally
Number of subjects: 24
Study 7303703 — intervention group
Group type: COMPARATOR
Intervention: beta‐methyldigoxin
Number of subjects: 24
Study 7303703 — intervention group
Group type: COMPARATOR
Intervention: beta‐acetyldigoxin
Number of subjects: 24
Study 30496003 — intervention group
Group type: EXPERIMENTAL
Intervention: Greening intervention
Number of subjects: 541
Study 30496003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mowing and trash cleanup intervention
Number of subjects: 541
Study 30496003 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 541
Study 28889792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 28889792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 28889792 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 28889792 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab vs. ipilimumab
Number of subjects: 0
Study 28889792 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab vs. ipilimumab
Number of subjects: 0
Study 25204200 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismoking ad targeting specific peer crowds
Number of subjects: 239
Study 24075842 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge management intervention using nurse care managers
Number of subjects: 60
Study 24075842 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge process)
Number of subjects: 60
Study 22053754 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 36
Study 22053754 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (Control)
Number of subjects: 36
Study 19196913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume/moderate intensity (12 miles/wk, 1,200 kcal/wk at 40-55% Vo(2peak), 200 min exercise/wk)
Number of subjects: 3
Study 19196913 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume/vigorous intensity (20 miles/wk, 2,000 kcal/wk at 65-80% Vo(2peak), 200 min/wk)
Number of subjects: 3
Study 19196913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume/vigorous intensity (12 miles/wk, 1,200 kcal/wk at 65-80% Vo(2peak), 125 min/wk)
Number of subjects: 3
Study 18167644 — intervention group
Group type: COMPARATOR
Intervention: Upper trunk SAT volume (highest tertile)
Number of subjects: 1184
Study 18167644 — intervention group
Group type: COMPARATOR
Intervention: VAT volume (highest tertile)
Number of subjects: 1184
Study 15078004 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg b.i.d. x 7 days)
Number of subjects: 0
Study 15078004 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (1 g t.i.d. x 7 days)
Number of subjects: 0
Study 11453959 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 12
Study 11453959 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 12
Study 9919896 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg daily for 1 week
Number of subjects: 135
Study 9919896 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 100 mg daily for 4 weeks
Number of subjects: 135
Study 8311214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (1 mg)
Number of subjects: 40
Study 8311214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine with adrenaline
Number of subjects: 40
Study 8311214 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and bupivacaine
Number of subjects: 40
Study 8311214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3138057 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamin 14 infusion
Number of subjects: 8
Study 31627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a more attractive painting on the previous trial
Number of subjects: 0
Study 31627213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 s exposure times
Number of subjects: 0
Study 31627213 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ms exposures followed by a mask
Number of subjects: 0
Study 28314613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose (ULD) protocols (I: 100kVp/50 mAs, II: 100kVp/75 mAs, III: 100kVp/100 mAs, IV: 120kVp/100 mAs)
Number of subjects: 40
Study 28314613 — intervention group
Group type: COMPARATOR
Intervention: Low dose (LD) protocols (I: 100kVp/75 mAs, II: 100kVp/100 mAs, III: 100kVp/150 mAs, IV: 120kVp/150 mAs)
Number of subjects: 40
Study 28314613 — intervention group
Group type: EXPERIMENTAL
Intervention: K-IMR CR 1 in the ULD group
Number of subjects: 40
Study 26074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidal deep brain stimulation (DBS)
Number of subjects: 13
Study 26074391 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed in the abstract)
Number of subjects: 13
Study 23504379 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention (MIN)
Number of subjects: 881
Study 23504379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (INT)
Number of subjects: 881
Study 23504379 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 881
Study 21542427 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 140
Study 21542427 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 140
Study 20001809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic venous outflow occlusion (HVOO)
Number of subjects: 39
Study 20001809 — intervention group
Group type: COMPARATOR
Intervention: Non-HVOO
Number of subjects: 39
Study 20001809 — intervention group
Group type: EXPERIMENTAL
Intervention: HVOO
Number of subjects: 39
Study 16731321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium plus 3 mg/kg lidocaine
Number of subjects: 40
Study 16731321 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 mg/kg lidocaine diluted with saline)
Number of subjects: 40
Study 15256690 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Rhodiola rosea intake (200 mg extract containing 3% rosavin + 1% salidroside)
Number of subjects: 24
Study 15256690 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Rhodiola rosea intake (200 mg extract)
Number of subjects: 24
Study 10502865 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner and Engle operation span task
Number of subjects: 33
Study 8858190 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 0
Study 8858190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (pergolide, bromocriptine, cabergoline)
Number of subjects: 0
Study 8858190 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechol-O-methyltransferase inhibitors (tolcapone, entacapone)
Number of subjects: 0
Study 8858190 — intervention group
Group type: COMPARATOR
Intervention: Levodopa therapy
Number of subjects: 0
Study 8858190 — intervention group
Group type: COMPARATOR
Intervention: Selegiline therapy
Number of subjects: 0
Study 1862015 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen controlled-release tablet (CRT)
Number of subjects: 74
Study 1862015 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg ibuprofen controlled-release tablet (CRT)
Number of subjects: 74
Study 1862015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 6869899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally the evening before and 300 mg intramuscularly between 1 and 3 h preoperatively)
Number of subjects: 126
Study 6869899 — intervention group
Group type: COMPARATOR
Intervention: Antacid (30 ml of Mylanta-II orally on both occasions)
Number of subjects: 126
Study 31773430 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Intervention
Number of subjects: 0
Study 31773430 — intervention group
Group type: EXPERIMENTAL
Intervention: Email-Counseling
Number of subjects: 0
Study 31773430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29930429 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers at night (experimental group)
Number of subjects: 46
Study 29930429 — intervention group
Group type: COMPARATOR
Intervention: Routine examination (control group)
Number of subjects: 46
Study 26945451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 26945451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24499830 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 26
Study 24499830 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 26
Study 23285647 — intervention group
Group type: EXPERIMENTAL
Intervention: Octrestatin injected perioperatively
Number of subjects: 105
Study 23285647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no octrestatin applied)
Number of subjects: 105
Study 18838500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (pramipexole 0.5 mg)
Number of subjects: 20
Study 18838500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine antagonist (sulpiride 400 mg)
Number of subjects: 20
Study 18507543 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS)
Number of subjects: 400
Study 18507543 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer-based pacing
Number of subjects: 400
Study 15963090 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 94
Study 15963090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 94
Study 15963090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 12904518 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy with micronized 17beta‐estradiol alone
Number of subjects: 226
Study 12904518 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol plus sequentially administered medroxyprogesterone acetate
Number of subjects: 226
Study 12904518 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 226
Study 10534213 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of GERD
Number of subjects: 268
Study 10534213 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD patients without comorbidity
Number of subjects: 268
Study 10534213 — intervention group
Group type: EXPERIMENTAL
Intervention: Study patients
Number of subjects: 268
Study 8889422 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of 0.01 mg kg‐1 followed by 0.07 mg kg‐1 after 3-4 min
Number of subjects: 40
Study 8889422 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of 0.015 mg kg‐1 followed by 0.065 mg kg‐1 after 3-4 min
Number of subjects: 40
Study 8889422 — intervention group
Group type: COMPARATOR
Intervention: Single bolus injection of 0.08 mg kg‐1
Number of subjects: 40
Study 1911500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 75 micrograms fentanyl
Number of subjects: 0
Study 1911500 — intervention group
Group type: COMPARATOR
Intervention: 3% 2-chloroprocaine
Number of subjects: 0
Study 1911500 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% 2-chloroprocaine with 75 micrograms fentanyl
Number of subjects: 0
Study 1911500 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study 6308441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg daily p.o.
Number of subjects: 38
Study 6308441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31192738 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of honey with an ORS at every diarrhea episode
Number of subjects: 72
Study 31192738 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of honey added to an ORS at every diarrhea episode
Number of subjects: 72
Study 29047408 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-43 (rikkunshito)
Number of subjects: 60
Study 29047408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27207028 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing® Applicator
Number of subjects: 325
Study 27207028 — intervention group
Group type: COMPARATOR
Intervention: Fingers-only method
Number of subjects: 325
Study 24578471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% sodium bicarbonate hydration (250 mL) prior to CE-CT
Number of subjects: 570
Study 24578471 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline hydration (1000 mL) prior to and after CE-CT
Number of subjects: 570
Study 24578471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% sodium bicarbonate hydration
Number of subjects: 570
Study 24578471 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline hydration
Number of subjects: 570
Study 21840102 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 14
Study 21840102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 14
Study 20579907 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training group
Number of subjects: 21
Study 20579907 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment Group
Number of subjects: 21
Study 17852006 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based case management for a six-month period
Number of subjects: 0
Study 17852006 — intervention group
Group type: COMPARATOR
Intervention: Usual self-directed care
Number of subjects: 0
Study 17852006 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management participants' use of community services
Number of subjects: 0
Study 16117878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dose of 25.2 to 30.6 Gy in 1.8 to 2.0 Gy per fraction
Number of subjects: 51
Study 16117878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCI)
Number of subjects: 51
Study 16117878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 51
Study 11801880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cuff brachytherapy
Number of subjects: 0
Study 11801880 — intervention group
Group type: COMPARATOR
Intervention: Whole pelvic radiation
Number of subjects: 0
Study 10387387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program based on a multidisciplinary team process
Number of subjects: 500
Study 10387387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 500
Study 10387387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study 1440822 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg twice daily for 21 days
Number of subjects: 112
Study 1440822 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg once daily for 21 days
Number of subjects: 112
Study 1440822 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 112
Study 1440822 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (both dosages)
Number of subjects: 112
Study 3698061 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated potassium chloride (KCl) 60 mEq/day (20 mEq TID)
Number of subjects: 120
Study 3698061 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax/polymer matrix tablet 60 mEq/day (20 mEq TID)
Number of subjects: 120
Study 3698061 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-in-liquid formulation 60 mEq/day (20 mEq TID)
Number of subjects: 120
Study 3698061 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 120
Study 29383408 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of nasal salmon calcitonin daily for three months
Number of subjects: 21
Study 29383408 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 21
Study 29383408 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of nasal salmon calcitonin
Number of subjects: 21
Study 26850727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-sex CR
Number of subjects: 169
Study 26850727 — intervention group
Group type: EXPERIMENTAL
Intervention: Women-only CR
Number of subjects: 169
Study 26850727 — intervention group
Group type: COMPARATOR
Intervention: Home-based CR
Number of subjects: 169
Study 26418770 — intervention group
Group type: EXPERIMENTAL
Intervention: EIP transfer with neutral wrist positioning (Group I, 12 cases)
Number of subjects: 24
Study 26418770 — intervention group
Group type: EXPERIMENTAL
Intervention: EIP transfer with full extension state (Group II, 12 cases)
Number of subjects: 24
Study 26418770 — intervention group
Group type: COMPARATOR
Intervention: Comparison of thumb motion, grip strength, pinch power, and Disabilities of the Arm, Shoulder, and Hand questionnaire score between Group I and Group II
Number of subjects: 24
Study 23586624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperiodontal probing (before incision/BI)
Number of subjects: 9
Study 23586624 — intervention group
Group type: COMPARATOR
Intervention: Transsurgical probing (after incision/AI)
Number of subjects: 9
Study 23586624 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of BI and AI methods
Number of subjects: 9
Study 22092542 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview in addition to classical consultation
Number of subjects: 0
Study 22092542 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation (Control)
Number of subjects: 0
Study 22092542 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 0
Study 18425398 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300 mg/day, three days after TACE)
Number of subjects: 30
Study 18425398 — intervention group
Group type: COMPARATOR
Intervention: Control (TACE alone)
Number of subjects: 30
Study 16607097 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day
Number of subjects: 60
Study 16607097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12892766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) with Sr-90
Number of subjects: 138
Study 10848883 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg
Number of subjects: 9